从文献看，好像可以，下面文献中TARCEVA被用来治脑部癌症。
Tarceva Produces Responses in Recurrent GBM
Researchers from the Cleveland Clinic Brain Tumor Institute have reported that Tarceva®
(erlotinib) produced responses in more than 40% of patients with
glioblastoma multiforme. These results were presented at the 29th European Society of Medical Oncology (ESMO) Congress held in Vienna, Austria, October 29 - November 3, 2004.
克利夫兰诊所脑肿瘤研究所科研究工作者报道tarceva的® （ erlotinib ），在 40 ％以上的多形性恶性胶质瘤患者有反应。
。这些成果均在29欧洲社会肿瘤内科（ esmo ）大会在奥地利维也纳举行， 10月29日-2 004年1 1月3日。
Approximately 17,500 people are diagnosed with primary brain
cancer in the United States each year. Primary brain
cancer is cancer that originates in the brain and has not spread from cancer already located elsewhere in the body. Glioblastoma is one of the most common, and fatal, types of primary brain
cancer.
When glioblastoma is present, glial cells become malignant and grow out
of control. Glial cells are the most abundant cells present in the
nervous system, providing many supportive functions that facilitate the
majority of processes conducted by neurons (cells that transmit
impulses between the brain, spinal column and nerves). Standard treatment options for glioblastoma consist of surgical removal of the cancer
if possible, radiation therapy and/or chemotherapy. However, even with
the most aggressive treatment available, most patients will survive
less than one year after diagnosis. Because of the poor prognosis for
patients with this disease, researchers are attempting to develop more
effective treatment strategies to improve survival of glioblastoma
patients.
One obstacle in the treatment of brain
cancer is the inability of the majority of chemotherapy agents to penetrate the blood-brain barrier. The blood-brain barrier is a membrane that surrounds the brain and spinal cord and protects the brain and nervous system by allowing only very select molecules to pass through. Tarceva® is a small molecule biological therapy that may pass through the blood brain barrier.
治疗脑肿瘤的障碍之一，是大多数化疗药物无法穿透血脑屏障。血脑屏障是一个膜包围脑和脊髓，保护脑和神经系统只允许极受选择的分子通过。 ® tarceva是一个小分子生物学治疗方法，可通过血脑屏障。
Tarceva®
is an epidermal growth factor receptor (EGFR) inhibitor. EGFRs are
small proteins that are found on the surface of all cells. EGFR binds
exclusively to small proteins circulating in the blood called growth
factors. The binding action between EGFR and growth factors stimulates
biological processes within the cell to promote growth of a cell in a
strictly controlled manner. However, in many cancer
cells, EGFR is either abundantly overexpressed or the EGFR biological
processes that normally stimulate cell growth are constantly active,
leading to the uncontrolled and excessive growth of the cancer cell.
There were 30 patients included in the Cleveland Clinic study. Patients were treated with 150 mg of Tarceva®
per day until tumor progression or study withdrawl. Approximately 43%
of patients (13/30) responded to treatment based on MRI. Six patients
had a greater than 50% reduction in tumor size and 7 patients had
stable disease for 3 months or more. Six months after treatment, 27% of
patients were free of cancer progression. Notably, more than 10% of patients were progression free at one year after treatment. Tarceva® was well tolerated; there were no grade 3 or 4 side effects.
Reference: Vogelbaum MA, Peereboom D,
Stevens GH, et al. Phase II study of single agent therapy with the EGFR
tyrosine kinase inhibitor erlotinib in recurrent glioblastoma
multiforme. Proceedings from the 29th ESMO Congress, Vienna, Austria, October 29 - November 3, 2004; (Abstract #783).
IP卡
狗仔卡
发表于 2007-8-23 20:36:59
显身卡